View these presentation slides showing data from a recent prospective, randomised controlled phase IIIb study for 4F-PCC.
Oral Anticoagulation Reversal
Resources
In This Section
- Administration of 4-factor prothrombin complex concentrate as an antidote for intracranial bleeding in patients taking direct factor Xa inhibitors
- Comparison of novel oral anticoagulants versus vitamin K antagonists in patients with chronic kidney disease
- Increased risk of volume overload with plasma compared with four-factor prothrombin complex concentrate for urgent vitamin K antagonist reversal
- Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents
- Thromboembolic events after vitamin K antagonist reversal with 4-factor prothrombin complex concentrate: exploratory analyses of two randomized, plasma-controlled studies
- Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants
Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase IIIb randomised trial
View this educational slide deck which discusses 4F PCC versus plasma in Vitamin K antagonist reversal in a phase 3b open-label randomised trial.
Job number: KCT16-01-0010
Developed by EPG Health for Medthority in collaboration with CSL Behring, with content provided by CSL Behring.
Not intended for Healthcare Professionals outside Europe.